Healthcare / BiotechnologyShanghai
$40.68
-1.32 (-3.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-31.6M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.8%
↓Gross Margin
67.1%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-17.9%
FCF CAGR
—
FCF margin
-63.0%
FCF / Net income
1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $146.4M · net income $-77.8M · FCF $-92.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $146.4M | $146.4M | $127.6M | $153.2M | $264.6M |
| Net Income | $-77.8M | $-77.8M | $-54.4M | $12.8M | $90.7M |
| EBITDA | $-37.9M | $-37.9M | $-19.3M | $32.4M | $130.7M |
| EPS | -1.11 | -1.11 | -0.78 | 0.18 | 1.59 |
| Gross Margin | 67.1% | 67.1% | 62.4% | 75.7% | 86.3% |
| Operating Margin | -45.5% | -45.5% | -43.4% | -3.8% | 42.7% |
| Net Margin | -53.1% | -53.1% | -42.7% | 8.4% | 34.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Current Ratio | 23.22 | 23.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-92.2M | $-92.2M | $-31.6M | $24.2M | $-33.4M |
| Returns | |||||
| ROE | -3.8% | -3.8% | -2.6% | 0.6% | 4.1% |
| Valuation | |||||
| P/E | — | — | — | 288.89 | 52.99 |
| EV/EBITDA | — | — | — | 90.16 | 30.27 |
| P/B | 1.40 | 1.40 | 1.08 | 1.70 | 2.18 |
| Growth & Yield | |||||
| Revenue Growth | 14.8% | 14.8% | -16.7% | -42.1% | — |
| EPS Growth | -42.3% | -42.3% | -533.3% | -88.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.78 → -1.11
Residual
+16.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.